1.Dunmire, SK, Verghese, PS and Balfour, HH (2018) Primary Epstein–Barr virus infection. Journal of Clinical Virology 102, 84–92.
2.Epstein, MA and Barr, YM (1964) Cultivation in vitro of human lymphoblasts from Burkitt's malignant lymphoma. The Lancet 1, 252–253.
3.Epstein, M, Achong, B and Barr, Y (1964) Virus particles in cultured lymphoblasts from Burkitt's lymphoma. The Lancet 1, 702–703.
4.Zur Hausen, H et al. (1970) EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228, 1056–1058.
5.Hjalgrim, H, Friborg, J and Melbye, M (2007) The epidemiology of EBV and its association with malignant disease. In Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Chapter 53. Cambridge University Press.
6.Moreno, MA et al. (2018) Molecular signature of Epstein–Barr virus infection in MS brain lesions. Neurology(r) Neuroimmunology & Neuroinflammation 5, .
7.Sokal, EM et al. (2007) Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein–Barr virus vaccine in healthy young adults. The Journal of Infectious Diseases 196, 1749–1753.
8.Ogembo, J et al. (2015) A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice. Journal of Translational Medicine 13, 50.
9.Kanekiyo, M et al. (2015) Rational design of an Epstein–Barr virus vaccine targeting the receptor-binding site. Cell 162, 1090–1100.
10.Balfour, HH et al. (2013) Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein–Barr virus infection in university students. Journal of Infectious Diseases 207, 80–88.
11.Grimm, JM et al. (2016) Prospective studies of infectious mononucleosis in university students. Clinical & Translational Immunology 5, e94–e96.
12.Parry, JV, Perry, KR and Mortimer, PP (1987) Sensitive assays for viral antibodies in saliva: an alternative to tests on serum. Lancet (London, England) 2, 72–75.
13.Archibald, DW et al. Secretory IgA Antibodies to Human Immunodeficiency Virus in the Parotid Saliva of Patients with AIDS and AIDS-Related Complex. The Journal of Infectious Diseases 155, 793–796.
14.Vyse, AJ et al. (1997) Detection of IgG antibody to Epstein–Barr virus viral capsid antigen in saliva by antibody capture radioimmunoassay. Journal of Virological Methods 63, 93–101.
15.Balfour, HH et al. (2005) A prospective clinical study of Epstein–Barr virus and host interactions during acute infectious mononucleosis. The Journal of Infectious Diseases 192, 1505–1512.
16.Florkowski, CM (2008) Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests. The Clinical Biochemist. Reviews 29(Suppl 1) S83–S87.
17.McHugh, ML (2012) Interrater reliability: the kappa statistic. Biochemia Medica 22, 276–282.
18.Hatipoğlu, H et al. (2007) Impact of the distinct sampling area on volumetric features of gingival crevicular fluid. Journal of Periodontology 78, 705–715.
19.Guentsch, A et al. (2011) Comparison of gingival crevicular fluid sampling methods in patients with severe chronic periodontitis. Journal of Periodontology 82, 1051–1060.
20.Nokes, DJ et al. (1998) An evaluation of oral-fluid collection devices for the determination of rubella antibody status in a rural Ethiopian community. Transactions of the Royal Society of Tropical Medicine and Hygiene 92, 679–685.
21.Hodinka, RL, Nagashunmugam, T and Malamud, D (1998) Detection of human immunodeficiency virus antibodies in oral fluids. Clinical and Diagnostic Laboratory Immunology 5, 419–426.